Charles River Laboratories International (CRL) Cost of Revenue (2009 - 2025)

Charles River Laboratories International's Cost of Revenue history runs 17 years deep, the most recent figure standing at $249.3 million for Q4 2025.

• In Q4 2025, Cost of Revenue fell 81.75% year-over-year to $249.3 million; the TTM figure through Dec 2025 stood at $1.8 billion (down 27.18% YoY), while the FY2025 annual figure was $576.2 million, down 66.05% from the prior year.
• Cost of Revenue was $249.3 million for Q4 2025 at Charles River Laboratories International, down from $408.1 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $1.4 billion in Q4 2024 to a low of -$1.0 billion in Q4 2021.
• Historically, Cost of Revenue has averaged $396.2 million across 5 years, with a median of $455.4 million in 2021.
• The sharpest annual moves came in 2023 and 2025: Cost of Revenue soared 653.48% in 2023, then plunged 81.75% in 2025.
• A 5-year view of Cost of Revenue shows it stood at -$1.0 billion in 2021, then jumped by 160.23% to $603.1 million in 2022, then plunged by 47.19% to $318.5 million in 2023, then soared by 328.74% to $1.4 billion in 2024, then slumped by 81.75% to $249.3 million in 2025.
• The last three Cost of Revenue figures came in at $249.3 million (Q4 2025), $408.1 million (Q3 2025), and $584.9 million (Q2 2025), per Business Quant data.